Microenvironment for leukemia extramedullary infiltration

doi:10.3760/cma.j.issn.1673-422X.2014.11.016

Abstract

Abstract: Extramedullary infiltration is one of the reasons of relapse and death for leukemia patients. Reaearches increasingly show that extramedullary microenvironment plays a pivotal role on progress and relapse of leukemia. Extramedullary infiltration of leukemia is the result of interactions among many factors and many steps, involving liver, spleen, central nervous system, thymus and other tissues and organs.

Key words: Leukemia, Leukemic infiltration, recurrence, Extramedullary microenvironment

WANG Hui, SHI Jun. Microenvironment for leukemia extramedullary infiltration[J]. Journal of International Oncology, 2014, 41(11): 851-854.

References

［1］ Dores GM, Devesa SS, Curtis RE, et al. Acute leukemia incidence and patient survival among children and adults in the United States, 20012007［J］. Blood, 2012, 119(1):3443. ［2］ Kobayashi R, Tawa A, Hanada R, et al. Extramedullary infiltration at diagnosis and prognosis in children with acute myelogenous leukemia［J］. Pediatr Blood Cancer, 2007, 48(4):393398. ［3］ Yang LL, Gan SL, Liu YF, et al. Clinical characteristics of CD56(+) patients with acute monocytic leukemia and their prognostic significance［J］. Zhongguo Shi Yan Xue Ye Xue Za Zhi, 2013, 21(3):596600. ［4］ Shimizu H, Saitoh T, Hatsumi N, et al. Prevalence of extramedullary relapses is higher after allogeneic stem cell transplantation than after chemotherapy in adult patients with acute myeloid leukemia［J］. Leuk Res, 2013, 37(11):14771481. ［5］ Ge L, Ye F, Mao X, et al. Extramedullary relapse of acute leukemia after allogeneic hematopoietic stem cell transplantation: different characteristics between acutemyelogenous leukemia and acute lymphoblastic leukemia［J］.Biol Blood Marrow Transplant,2014, 20（7）： 10401047. ［6］ Jacamo R, Chen Y, Wang Z, et al. Reciprocal leukemiastroma VCAM1/VLA4dependent activation of NFkappaB mediates chemoresistance［J］. Blood, 2014, 123(17):26912702. ［7］ Ishikawa F, Yoshida S, Saito Y, et al. Chemotherapyresistant human AML stem cells home to and engraft within the bonemarrow endosteal region［J］. Nat Biotechnol, 2007, 25(11):13151321. ［8］ Saito Y, Uchida N, Tanaka S, et al. Induction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AML［J］. Nat Biotechnol, 2010, 28(3):275280. ［9］ Borowitz MJ, Devidas M, Hunger SP, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children′s Oncology Group study［J］. Blood, 2008, 111(12):54775485. ［10］ Kato I, Niwa A, Heike T, et al. Identification of hepatic niche harboring human acute lymphoblastic leukemic cells via the SDF1/CXCR4 axis［J］. PLoS One, 2011, 6(11):e27042. ［11］马玉花，邹亚伟. 白血病肝损伤的研究进展［J］. 中国小儿血液与肿瘤杂志，2013, 18（2）:9396. ［12］ Schemionek M, Spieker T, Kerstiens L, et al. Leukemic spleen cells are more potent than bone marrowderived cells in a transgenic mouse model of CML［J］. Leukemia, 2012, 26(5):10301037. ［13］ Sengupta A, Arnett J, Dunn S, et al. Rac2 GTPase deficiency depletes BCRABL+ leukemic stem cells and progenitors in vivo［J］. Blood, 2010, 116(1):8184. ［14］ Shaked Y, Cervi D, Neuman M, et al. The splenic microenvironment is a source of proangiogenesis/inflammatory mediators accelerating the expansion of murine erythroleukemic cells［J］. Blood, 2005, 105(11):45004507. ［15］ Feng SR, Chen ZX, Cen JN, et al. Disruption of blood brainbarrier by leukemic cells in central nervous system leukemia［J］. Zhonghua Xue Ye Xue Za Zhi, 2011, 32(5):289293. ［16］ Pui CH, Howard SC. Current management and challenges of malignant disease in the CNS in paediatric leukaemia［J］. Lancet Oncol, 2008, 9(3):257268. ［17］ Feng S, Cen J, Huang Y, et al. Matrix metalloproteinase2 and 9 secreted by leukemic cells increase the permeability of bloodbrain barrier by disrupting tight junction proteins［J］. PLoS One, 2011, 6(8):e20599. ［18］ Raanani P, Shpilberg O, BenBassat I. Extramedullary disease and targeted therapies for hematological malignanciesis the association real?［J］. Ann Oncol, 2007, 18(1):712. ［19］ Tsukamoto S, Ota S, Ohwada C, et al. Extramedullary blast crisis of chronic myelogenous leukemia as an initial presentation［J］. Leuk Res Rep, 2013, 2(2):6769.

[1]	Chen Hongjian, Zhang Suqing. Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients [J]. Journal of International Oncology, 2024, 51(6): 344-349.
[2]	Liu Pingping, He Xuefang, Zhang Yi, Yang Xu, Zhang Shanshan, Ji Yifei. Risk factors of postoperative recurrence in patients with primary brain glioma and prediction model construction [J]. Journal of International Oncology, 2024, 51(4): 193-197.
[3]	Teng Yuan, Li Lijuan, Zhang Liansheng. Progress of MCL-1 and its inhibitors in hematologic malignancies [J]. Journal of International Oncology, 2024, 51(2): 119-122.
[4]	Zhang Lu, Jiang Hua, Lin Zhou, Ma Chenying, Xu Xiaoting, Wang Lili, Zhou Juying. Analysis of curative effect and prognosis of immune checkpoint inhibitor in the treatment of recurrent and metastatic cervical cancer [J]. Journal of International Oncology, 2023, 50(8): 475-483.
[5]	Wang Jun, Jia Xiuhong. TGF-β/Smad signal pathway and acute leukemia [J]. Journal of International Oncology, 2023, 50(8): 498-502.
[6]	Wang Ting, Li Wenqian, Xie Youbang. Correlation between hypoxia and the oxygen sensing pathway in acute myeloid leukemia cells [J]. Journal of International Oncology, 2023, 50(8): 503-507.
[7]	Yang Lirong, Wang Yufeng. Construction of machine learning models for predicting the risk of postoperative distant metastasis recurrence in serous ovarian cancer [J]. Journal of International Oncology, 2023, 50(4): 220-226.
[8]	Ma Peihan, Zhang Lingming, Lu Ning, Zhang Mingxin. Effect of anesthesia on the recurrence and metastasis of hepatocellular carcinoma [J]. Journal of International Oncology, 2023, 50(2): 117-121.
[9]	Zhang Ting, Jia Xiuhong. Research progress of pyroptosis in leukemia [J]. Journal of International Oncology, 2023, 50(11): 696-700.
[10]	Zhang Lu, Zhou Juying, Ma Chenying, Lin Zhou. Advances in immunotherapy for recurrent and metastatic cervical cancer [J]. Journal of International Oncology, 2022, 49(9): 517-520.
[11]	Wu Puyuan, Qi Liang, Wang Tao, Shi Minke, Sun Yuwei, Wang Lifeng, Liu Baorui, Yan Jing, Ren Wei. Efficacy of postoperative radiotherapy based on modified clinical target volume according to high-frequency recurrence regions in patients with esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2022, 49(8): 464-472.
[12]	Lu Jialing, Huang Huijuan, Liu Dan, Chen Yanxin, Ma Xiao, Wu Depei. Efficacy and safety of blinatumomab in the treatment of B-cell acute lymphoblastic leukemia [J]. Journal of International Oncology, 2022, 49(8): 494-498.
[13]	Peng Chen, Xie Yintong, Zhang Xin, Xie Peng. Research progress of maintenance therapy for cervical cancer [J]. Journal of International Oncology, 2022, 49(7): 430-435.
[14]	Zhu Yishuo, Cui Yujie, Liu Qi, Li Jun, Fan Yuechao. Analysis of risk factors and prediction model establishment for early postoperative recurrence in glioma patients [J]. Journal of International Oncology, 2022, 49(2): 79-83.
[15]	Zhou Xinyu, Jia Xiuhong. Research progress of ferroptosis in the treatment of leukemia [J]. Journal of International Oncology, 2022, 49(12): 759-762.